On the other hand, sunitinib is active against mutations in KIT exons 13/14 but not exons 17/18,15, 19, 26, 42, 43 which may explain the findings in our analysis that ripretinib might be the optimal recommendation as a post‐first‐line treatment for advanced GIST following imatinib failure. Here, KIT is linked to gastrointestinal stromal tumor.